stockrow
Friday 6 November 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024.
- Revenue
- +21.5%
- EPS
- +25.0%
- Free cash flow
- +40.9%
- Total debt
- +1.48%
Quarter to September 2026, against a year earlier
7.83
0.46
+6.24%
Follow TKNO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 21 | 31 | 37 | 41 | 37 | 38 | 41 | 46 | +11.8% | 46 | 53 | 62 | +15.4% | |
| Gross margin, % | — | — | — | 37.05 | 56.73 | 47.76 | 42.19 | 28.07 | 19.16 | 33.17 | 36.43 | (3.9) pt | ||||||
| EBT | — | — | — | (5) | 5 | (13) | (49) | (37) | (27) | (17) | (16) | +24.9% | ||||||
| EBT margin, % | — | — | — | (21.83) | 15.10 | (34.25) | (119.24) | (101.07) | (71.09) | (42.45) | (34.66) | (20.6) pt | ||||||
| Net income | — | 0 | — | (1) | 4 | (10) | (47) | (37) | (27) | (17) | (16) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.80 | 8.70 | 2.29 | 1.47 | 1.15 | 0.81 | 0.76 | 0.86 | (0.8%) | |||||
| Earnings | — | — | — | (0.06) | 0.17 | (0.61) | (1.69) | (1.16) | (0.57) | (0.32) | (0.29) | +32.2% | ||||||
| Cash flow | — | — | — | 0.09 | 0.70 | (0.56) | (0.98) | (0.59) | (0.27) | (0.16) | (0.10) | n/m | ||||||
| Capex | — | — | — | 0.00 | (1.52) | (1.24) | (1.00) | (0.24) | (0.02) | (0.02) | (0.02) | n/m | ||||||
| Free cash flow | — | — | — | 0.09 | (0.82) | (1.80) | (1.98) | (0.83) | (0.29) | (0.18) | (0.12) | n/m | ||||||
| Book value | — | — | — | 1.86 | 4.66 | 8.90 | 3.56 | 2.83 | 1.76 | 1.29 | 1.11 | (6.0%) | ||||||
| Shares, m | — | — | — | 26 | 4 | 16 | 28 | 32 | 47 | 53 | 54 | +12.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 64.73 | 64.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.5 | |||||
| P/S | — | — | — | 2.63 | 2.63 | 8.93 | 3.81 | 3.30 | 10.34 | 5.02 | 9.15 | 5.2 | ||||||
| P/B | — | — | — | 5.53 | 5.53 | 2.30 | 1.58 | 1.34 | 4.74 | 2.96 | 7.03 | 3.4 | ||||||
| EV/Sales | — | — | — | 2.55 | 2.55 | 6.88 | 3.38 | 2.93 | 9.89 | 4.91 | 9.17 | 4.7 | ||||||
| EV/FCF | — | — | — | (19.63) | (19.63) | (8.77) | (2.52) | (4.05) | (27.89) | (20.33) | (65.97) | (14.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 2 | 3 | (9) | (27) | (19) | (12) | (9) | (6) | n/m | |||||
| Capex | — | — | — | (3) | (5) | (20) | (28) | (8) | (1) | (1) | (1) | (14.1%) | ||||||
| Free cash flow | — | — | — | 2 | (3) | (29) | (56) | (27) | (13) | (10) | (6) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 10 | 12 | 93 | 50 | 37 | 32 | 27 | 23 | +18.3% | |||||
| Net debt | — | — | — | (10) | (5) | (76) | (18) | (15) | (17) | (8) | (3) | (2.6%) | ||||||
| Shareholders’ equity | — | — | — | 49 | 17 | 143 | 100 | 90 | 82 | 69 | 60 | +6.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (4.92) | 1.00 | (8.55) | (29.78) | (26.19) | (21.62) | (15.52) | (15.79) | (10.6) pt | |||||
| ROIC | — | — | — | 0.00 | 25.04 | (11.11) | (37.92) | (29.71) | (24.95) | (17.52) | (16.60) | (17.5) pt | ||||||
| ROE | — | — | — | (9.70) | 4.10 | (12.26) | (39.05) | (38.73) | (31.02) | (22.83) | (24.12) | (13.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 194 | 237 | 290 | 211 | 173 | 158 | — | (4.0%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.16 | 0.16 | 0.14 | 0.17 | 0.22 | 0.26 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
Alpha Teknova, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals, Inc. | $665.9M | 4.3× | 2.9× | +9.00% (above 0%: growing) | +44.00% (above 0%: growing) | +41.66% (above 0%: growing) | 100.00% | 70.00% | Compare |
| EVO Evotec AG | $630.4M | — (loss-making) | — (loss-making) | −12.98% (below 0%: shrinking) | n/m | −9,727.20% (below 0%: shrinking) | (1.00%) | (77.50%) | Compare |
| TKNO Alpha Teknova, Inc. | $486.2M | — (loss-making) | — (loss-making) | +21.52% (above 0%: growing) | n/m | +40.94% (above 0%: growing) | 37.99% | (25.24%) | |
| AQST Aquestive Therapeutics, Inc. | $460.0M | — (loss-making) | — (loss-making) | −40.99% (below 0%: shrinking) | n/m | +40.78% (above 0%: growing) | 52.28% | (191.46%) | Compare |
| EOLS Evolus, Inc. | $448.8M | — (loss-making) | — (loss-making) | +13.03% (above 0%: growing) | n/m | +77.73% (above 0%: growing) | 65.02% | (10.81%) | Compare |
| TLRY Tilray Brands, Inc. | $415.3M | — (loss-making) | — (loss-making) | +22.74% (above 0%: growing) | n/m | −159.66% (below 0%: shrinking) | 30.14% | (9.35%) | Compare |
| KMDA Kamada Ltd. | $396.3M | 18.1× | — (loss-making) | +22.72% (above 0%: growing) | +23.08% (above 0%: growing) | +165.71% (above 0%: growing) | 40.91% | 17.32% | Compare |
| ACB Aurora Cannabis Inc. | $341.2M | — (loss-making) | — (loss-making) | −31.15% (below 0%: shrinking) | n/m | −293.56% (below 0%: shrinking) | 52.73% | (12.92%) | Compare |
| CGC Canopy Growth Corporation | $283.5M | — (loss-making) | — (loss-making) | +12.41% (above 0%: growing) | n/m | −117.60% (below 0%: shrinking) | 27.40% | (27.24%) | Compare |
| Median of peers | $432.1M | — | — | +10.71% | — | −38.41% | 46.60% | (11.86%) |
Pay and ownership Proxy statement filed 21 April 2026
Ownership
Directors and executive officers, together
13.20%
Entities affiliated with Telegraph Hill Partners
70.40%
Irene Davis
6.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement